Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes

Kidney International

Volumn 63, Issue 1, 2003, Pages 64-71

  Laverman, Gozewijn D ^a,b   Van Goor, Harry ^a   Henning, Robert H ^a   De Jong, Paul E ^a   De Zeeuw, Dick ^a   Navis, Gerjan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adriamycin nephrosis; Dietary sodium; Gemopatrilat; Lisinopril; Proteinuria; Renoprotection; Vasopeptide inhibition

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; DRINKING WATER; GEMOPATRILAT; LISINOPRIL; SODIUM CHLORIDE; VASOPEPTIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FOCAL GLOMERULONEPHRITIS; HIGH SODIUM INTAKE; KIDNEY INJURY; KIDNEY STRUCTURE; MALE; NEPHROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; SCORING SYSTEM; SODIUM INTAKE; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE;

EID: 0037213059     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00708.x     Document Type: Article

References (34)

1. Ruggenenti P, Perna A, Mosconi L, et al: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int 53:1209-1216, 1998
2. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:754-762, 1995
3. Ruggenenti P, Perna A, Gherardi G, et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252-1256, 1998
4. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817, 2000
5. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989
6. Buter H, Hemmelder MH, Navis G, et al: The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13:1682-1685, 1998
7. Weber M: Emerging treatments for hypertension: Potential role for vasopeptidase inhibition. Am J Hypertens 12:139S-147S, 1999
8. Lipkin GW, Dawnay AB, Harwood SM, et al: Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure. Kidney Int 52:792-801, 1997
9. Maack T: Role of atrial natriuretic factor in volume control. Kidney Int 49:1732-1737, 1996
10. Trippodo NC, Robl JA, Asaad MM, et al: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 11:363-372, 1998
11. Taal MW, Nenov VD, Wong W, et al: Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051-2059, 2001
12. Cohen DS, Mathis JE, Dotson RA, et al: Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol 32:87-95, 1998
13. Cao Z, Burrell LM, Tikkanen I, et al: Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 60:715-721, 2001
14. Wapstra FH, van Goor H, de Jong PE, et al: Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis. J Pharmacol Toxicol Methods 41:69-73, 1999
15. Hubner RA, Kubota E, Casley DJ, et al: In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat. J Hypertens 19:941-946, 2001
16. Wapstra FH, van Goor H, Navis G, et al: Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci Colch 90:393-401, 1996
17. Raij L, Azar S, Keane W: Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26:137-143, 1984
18. Abbate M, Zoja C, Rottoli D, et al: Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates pro. J Am Soc Nephrol 10:804-813, 1999
19. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45(Suppl 45):S174-S178, 1994
20. Perico N, Delaini F, Lupini C, et al: Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney Int 36:57-64, 1989
21. Hildebrandt DA, Banks RO: Effect of atrial natriuretic factor on renal function in rats with nephrotic syndrome. Am J Physiol 254:F210-F216, 1988
22. Koepke JP, DiBona GF: Blunted natriuresis to atrial natriuretic peptide in chronic sodium-retaining disorders. Am J Physiol 252:F865-F871, 1987
23. Burrell LM, Farina NK, Balding LC, Johnston CI: Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension 36:1105-1111, 2000
24. Troughton RW, Rademaker MT, Powell JD, et al: Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure. Hypertension 36:523-530, 2000
25. Fried TA, McCoy RN, Osgood RW, Stein JH: Effect of atriopeptin II on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am J Physiol 250:F1119-F1122, 1986
26. Marin-Grez M, Fleming JT, Steinhausen M: Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 324:473-476, 1986
27. McKenna K, Smith D, Barrett P, et al: Angiotensin-converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria. Diabet Med 17:219-224, 2000
28. Prasad N, Clarkson PB, MacDonald TM, et al: Atrial natriuretic peptide increases urinary albumin excretion in men with type 1 diabetes mellitus and established microalbuminuria. Diabet Med 15:678-682, 1998
29. Ishi M, Hirata Y, Sugimoto T, et al: Effect of alpha-human atrial natriuretic peptide on proteinuria in patients with primary glomerular diseases. Clin Sci Colch 77:643-650, 1989
30. Ferro CJ, Spratt JC, Haynes WG, Webb DJ: Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97:2323-2330, 1998
31. Tikkanen T, Tikkanen I, Rockell MD, et al: Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 32:778-785, 1998
32. Quaschning T, D'Uscio LV, Shaw S, et al: Vasopeptidase inhibition restores renovascular endothelial dysfunction in salt-induced hypertension. J Am Soc Nephrol 12:2280-2287, 2001
33. Burrell LM, Droogh J, Man I, et al: Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 13:1110-1116, 2000
34. de Jong PE, Navis G, de Zeeuw D: Renoprotective therapy: Titration against urinary protein excretion. Lancet 354:352-353, 1999